11	A I' A	A	
Notice of Allowability	Application No.	Applicant(s)	
	09/889,515 Examiner	FAULL ET AL.	
		Art Unit	
	Robert Shiao	1626	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.			
1. This communication is responsive to <u>responses filed on 06/08, 2004</u> .			
2. The allowed claim(s) is/are <u>1-4, 6, 8-9, and 11, now are 1-8</u> .			
3. The drawings filed on are accepted by the Examiner.			
<ul> <li>4.  Acknowledgment is made of a claim for foreign priority un</li> <li>a)  All b)  Some* c)  None of the:</li> <li>1.  Certified copies of the priority documents have</li> <li>2.  Certified copies of the priority documents have</li> </ul>	been received.		
3. 🗵 Copies of the certified copies of the priority documents have been received in this national stage application from the			
International Bureau (PCT Rule 17.2(a)).			
* Certified copies not received:			
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.			
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.			
6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.			
(a) I including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached			
1) hereto or 2) to Paper No./Mail Date			
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date			
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).			
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.			
Attachment(s)			
1. Notice of References Cited (PTO-892)	5. Notice of Info	rmal Patent Application (PTO	)-152)
2.  Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Sur		·
3. A Information Disclosure Statements (PTO-1449 or PTO/SB/06 Paper No./Mail Date 0604	Paper No./M B), 7. ☐ Examiner's A	lail Date mendment/Comment	
4.   Examiner's Comment Regarding Requirement for Deposit		tatement of Reasons for Allov	wance
of Biological Material	9. 🗌 Other		
			$\propto$

Application/Control Number: 09/889,515 Page 2

Art Unit: 1626

## **DETAILED ACTION**

1. This application claims benefit of the foreign application: UNITED KINGDOM 9902459.8 with a filing date 02/05/1999.

2. Amendment of claims 1-4, and 8, and cancellation of claims 5, 7,10 in Paper No. 0604, dated June 8, 2004, is acknowledged. Claims 1-4, 6, 8-9, and 11 are pending in the application.

## Responses to Amendment

3. The rejection of claim 8 under 35 U.S.C. 112, second paragraph, has been overcome in Paper No. 0604, dated June 8, 2004. Since claim 10 has been cancelled, therefore, the rejection of claim 10 under 35 U.S.C. 112, first paragraph, is obviated.

## Reasons for Allowance

4. The following is an examiner's statement of reasons for allowance:

Claims 1-4, 6, 8-9, and 11 are neither anticipated nor rendered obvious over the art of record, and therefore are allowable. This invention relates to anti-inflammatory indole derivatives. The closest prior art is Kettle et al. US 6,737,435, disclose indol derivatives and their use as MCP-1 antagonist. The difference between prior art and instant claims is that the variable R<sup>4</sup> of instant compounds represents –NHSO<sub>2</sub> R<sup>15</sup>, while Kettle et al. represents hydrogen, halo, or methoxy at the same position. Suggestion for modification of above

Application/Control Number: 09/889,515

Art Unit: 1626

reference to obtain the instant compounds/compositions and methods of use, has not been found. Claims 1-4, 6, 8-9, and 11 are allowed.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

## Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert Shiao whose telephone number is (571) 272-0707. The examiner can normally be reached on 8:30 AM - 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph K. McKane can be reached on (571) 272-0699. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Art Unit: 1626

Joseph K. McKane Supervisory Patent Examiner Art Unit 1626

Robert Shiao, Ph.D. Patent Examiner Art Unit 1626

June 8, 2004